• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ACAD alert in real time by email

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Jan 3, 2025

    S&P SmallCap 600

    Addition

    Acadia Pharmaceuticals

    ACAD

    Health Care

    Jan 3, 2025

    S&P SmallCap 600

    Deletion

    Independent Bank Group

    IBTX

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com 

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

    SOURCE S&P Dow Jones Indices

    Get the next $ACAD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $IBTX
    $SPGI
    $SSB

    CompanyDatePrice TargetRatingAnalyst
    SouthState Bank Corporation
    $SSB
    7/25/2025$97.00 → $105.00Market Perform
    Hovde Group
    SouthState Bank Corporation
    $SSB
    5/21/2025$110.00Buy
    Jefferies
    ACADIA Pharmaceuticals Inc.
    $ACAD
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    SouthState Bank Corporation
    $SSB
    5/13/2025$106.00Buy
    Truist
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    SouthState Bank Corporation
    $SSB
    4/2/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    SouthState Bank Corporation
    $SSB
    4/1/2025$120.00Overweight
    Barclays
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    More analyst ratings

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith G Stacy bought $230,750 worth of shares (2,500 units at $92.30), increasing direct ownership by 7% to 39,546 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    8/4/25 10:55:38 AM ET
    $SSB
    Major Banks
    Finance

    Director Froetscher Janet P bought $324,821 worth of shares (3,338 units at $97.31), increasing direct ownership by 67% to 8,294 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    7/30/25 4:39:55 PM ET
    $SSB
    Major Banks
    Finance

    Director Froetscher Janet P bought $250,018 worth of shares (2,717 units at $92.02), increasing direct ownership by 138% to 4,689 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    3/11/25 4:10:14 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

    -- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, consistent with the Phase 3 LAVENDER™ trial that supported FDA approval and open-label LILAC, LILAC-2 and DAFFODIL studies Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide) under routine clinical care in the U.S. Findings included reported improvements in symptoms of Rett s

    9/12/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TARIFF FEARS DRIVE U.S. STOCKPILING IN AUGUST, WHILE MANUFACTURING WEAKENS IN EUROPE AND ASIA: GEP SUPPLY CHAIN VOLATILITY INDEX

    North America's supply chains get busier, with sharp stockpiling of components to guard against tariff-driven shortages and price inflationAsia's manufacturers cut purchases, led by Japan and Taiwan, and to a lesser extent ChinaEurope weakens further, dragged down by Germany and a sharp downturn in the UKCLARK, N.J., Sept. 11, 2025 /PRNewswire/ -- GEP Global Supply Chain Volatility Index, a leading economic indicator based on a monthly survey of 27,000 businesses, slipped to -0.39 in August, from -0.35 in July, signaling rising spare capacity as global supply chain activity cooled. The global figure concealed stark regional contrasts. North America was the outlier, with supply chains running

    9/11/25 8:23:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global ushers new era of open data access: Introduces S&P Capital IQ Identifiers on DUNL.org

    Customers can reduce time to value by seamlessly accessing S&P Capital IQ Identifiers via DUNL.org New enhancement brings over 25 million company records in both human and machine-readable formatsNEW YORK, Sept. 11, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the availability of the S&P Capital IQ Identifiers on Data Unlocked (DUNL.org), a comprehensive open data portal that provides organizations worldwide with free access to essential reference and master data. The release further solidifies the S&P Capital IQ ID as the standard company identifier for all S&P Global data, with over 25 million companies now available in both human and machine-readable formats on DUNL.

    9/11/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hovde Group reiterated coverage on South State with a new price target

    Hovde Group reiterated coverage of South State with a rating of Market Perform and set a new price target of $105.00 from $97.00 previously

    7/25/25 8:12:35 AM ET
    $SSB
    Major Banks
    Finance

    Jefferies initiated coverage on South State with a new price target

    Jefferies initiated coverage of South State with a rating of Buy and set a new price target of $110.00

    5/21/25 9:01:11 AM ET
    $SSB
    Major Banks
    Finance

    ACADIA Pharmaceuticals upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded ACADIA Pharmaceuticals from Hold to Buy and set a new price target of $35.00

    5/21/25 8:39:09 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Garofalo Elizabeth A. sold $41,560 worth of shares (1,600 units at $25.98), decreasing direct ownership by 6% to 25,382 units (SEC Form 4)

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    9/3/25 6:00:05 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Strategy Officer Young Stephen Dean gifted 2,750 shares, decreasing direct ownership by 6% to 46,534 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    8/28/25 4:34:48 PM ET
    $SSB
    Major Banks
    Finance

    CEO Corbett John C gifted 5,000 shares, decreasing direct ownership by 4% to 112,750 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    8/27/25 2:46:10 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    SEC Filings

    View All

    SouthState Bank Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Completion of Acquisition or Disposition of Assets, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - SouthState Bank Corp (0000764038) (Filer)

    9/4/25 4:41:33 PM ET
    $SSB
    Major Banks
    Finance

    SouthState Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - SouthState Corp (0000764038) (Filer)

    8/19/25 4:05:23 PM ET
    $SSB
    Major Banks
    Finance

    SEC Form N-PX filed by SouthState Corporation

    N-PX - SouthState Corp (0000764038) (Filer)

    8/13/25 3:48:58 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Mirion Technologies Set to Join S&P SmallCap 600

    NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Mirion Technologies Inc. (NYSE:MIR) will replace GMS Inc. (NYSE:GMS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 9. S&P 500 and 100 constituent Home Depot Inc. (NYSE:HD) acquired GMS in a deal that was completed today. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 9, 2025 S&P SmallCap 600 Addition Mirion Technologies MIR Information Technology September 9, 2025 S&P SmallCap 600 Deletion GMS GMS Industrials For more information about S&P Dow Jones Indices, please visit www

    9/4/25 5:28:00 PM ET
    $GMS
    $HD
    $MIR
    RETAIL: Building Materials
    Consumer Discretionary
    Industrial Machinery/Components
    Industrials

    S&P Global Announces Key Leadership Appointments for Mobility Business

    Scott Fredericks Named President of CARFAX Joe Lafeir to Serve as President of Mobility Business Solutions NEW YORK, Sept. 3, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of key leadership roles in the S&P Global Mobility ("Mobility") division, effective today. Scott Fredericks, current Chief Operating Officer of CARFAX, has been appointed President of CARFAX. He succeeds Bill Eager, who was recently appointed President of S&P Global Mobility and CEO designate upon completion of Mobility's planned separation from S&P Global into a standalone publ

    9/3/25 4:10:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Financials

    Live finance-specific insights

    View All

    Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

    - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2025. "Acadia continued to build momentum in the second qua

    8/6/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bill Eager Appointed President of S&P Global Mobility and CEO Designate of Planned Standalone Public Company

    Edouard Tavernier to Transition to Strategic Advisor Role Through September 30, 2025Company Separately Reports Second Quarter 2025 Results; Conference Call Today at 8:30 a.m. EDTNEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Bill Eager, Chief Executive Officer of CARFAX, as President of S&P Global Mobility ("Mobility"), effective August 15, 2025, and CEO designate upon completion of the previously announced planned separation of Mobility into a standalone public company. Mr. Eager succeeds Edouard Tavernier, who will remain with the Company as a strategic advisor through September 30, 2025, to support a smooth transition.

    7/31/25 7:17:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Reports Second Quarter Results

    NEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported second quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. Supplemental Information/Conference Call/Webcast Details:  The Company's senior management will review the second quarter 2025 earnings results on a conference call scheduled for today, July 31, at 8:30 a.m. EDT. Additional information presented on the conference call, as well as the Company's Supplemental slide content may be found on the Company's Inves

    7/31/25 7:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SouthState Corporation

    SC 13G/A - SouthState Corp (0000764038) (Subject)

    11/14/24 1:28:29 PM ET
    $SSB
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/24 6:48:52 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SouthState Corporation

    SC 13G - SouthState Corp (0000764038) (Subject)

    2/14/24 10:04:34 AM ET
    $SSB
    Major Banks
    Finance